Castle biosciences presents new data at astro 2023 highlighting risk-stratification performance of decisiondx®-scc in patients with cutaneous squamous cell carcinoma eligible for adjuvant radiation therapy

Friendswood, texas--(business wire)---- $cstl #astro23--castle will share new data on its decisiondx®-scc test at the american society for radiation oncology (astro) 2023 annual meeting.
CSTL Ratings Summary
CSTL Quant Ranking